NexImmune
NexImmune is a biotechnology company that develops innovative technologies to direct cell-mediated immune responses for treating a variety of diseases, including cancer, infectious, and autoimmune diseases.
Company Overview
NexImmune is at the forefront of developing novel technologies designed to harness natural biology for orchestrating precise cell-mediated immune responses. Their innovative approach is broad-reaching, addressing diseases including cancer, infectious diseases, and autoimmune disorders. NexImmune's versatility in adjusting immune responses to either amplify or dampen them to suitably treat varying conditions highlights its adaptive capabilities.
Advanced Immune Modulation Technology
NexImmune's AIM™ (Artificial Immune Modulation) technology platforms serve as the cornerstone of their therapeutic innovations. The company's AIM™ NT Platform, AIM™ ACT Adoptive Cellular Therapy, and AIM™ INJ Direct Injection are pivotal in customizing immune responses. These platforms enable targeted therapies for a spectrum of diseases, providing flexibility and precision in treatment.
Research Partnerships
NexImmune has extended a significant research collaboration with Yale University and JDRF focusing on Type 1 Diabetes. This partnership underscores the company's commitment to advancing research and therapeutic options for autoimmune diseases. Such collaborations are integral to the development and refinement of NexImmune's technologies and treatment methodologies.
Recent Funding
In a recent fundraising initiative, NexImmune successfully raised $3.67 million through a registered direct offering under Nasdaq rules. This financial boost is intended to further expand and expedite their research and development efforts, consolidating their stance in the biotech industry.
Headquarters
NexImmune is headquartered at 9119 Gaither Road, Gaithersburg, MD 20877. This location serves as the central hub for its research, development, and operational activities.